spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  guanfacine 

 HSMN NewsFeed - 28 Feb 2011
FDA Approves INTUNIV(R) (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Dec 2010
Shire Files Suit Against Impax and Watson
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Apr 2010
INTUNIV(TM) - Shire Files Suit Against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Sep 2009
Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Oct 2008
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 15 Jul 2008
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Jul 2008
Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 May 2008
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Apr 2008
Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2008
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2008
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 Feb 2008
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Jan 2008
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2008
Shire Announces Further Expansion Into Latin America
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2008
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Dec 2007
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 8 Nov 2007
Shire Expands its Human Genetic Therapies Pipeline Through In-Licensing Agreement With Amicus Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Nov 2007
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2007
David Mott Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Oct 2007
Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2007
FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Shire Divests Non-Core Product Portfolio to Almirall
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Oct 2007
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Sep 2007
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2007
Shire Voluntarily Withdraws a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 27 Jul 2007
Shire's New ADHD Medication, VYVANSE(TM) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2007
Shire Receives Approvable Letter From FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jun 2007
Shire In-Licenses JUVISTA(R) (Human TGFbeta3) From Renovo
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 May 2007
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of LIALDA(TM) (mesalamine) Presented at DDW
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 May 2007
FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 May 2007
VYVANSE(TM) (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2007
Shire Completes Acquisition of New River
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Apr 2007
Shire Successfully Completes Tender Offer for New River Shares
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Mar 2007
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 Mar 2007
Shire Begins External Search for President of Successful Human Genetic Therapies Business, on Retirement of David Pendergast at the End of 2007
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Mar 2007
UK Launch Expands Global Reach of FOSRENOL(R)
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Jan 2007
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Dec 2006
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Dr. Jeffrey Leiden Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2006
FOSRENOL(R) Data Show Evidence of Trends Towards Improved Bone Formation in CKD Stage 5 Patients, New Data Presented at ASN Meeting
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of a Meta-Analysis Comparing Stimulant Medications to Non-Stimulant Medications in Treating ADHD in Patients Aged 8 to 15
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2006
Shire Sues Andrx Pharmaceuticals, L.L.C.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
Biopharmaceuticals
 HSMN NewsFeed - 24 Aug 2006
Shire Announces NDA Submission of Guanfacine Extended Release for the Treatment of ADHD in Children and Adolescents
Biopharmaceuticals FDA
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.